Who are the winners and losers of the UK-US pharma deal—it depends which side you believe
Els Torreele, Martin McKee
原始摘要（英文原文）· Original abstract
Behind the UK’s “landmark” pharma deal with the US lies a costly surrender, with higher drug prices, weaker safeguards, and vague promises of investment, write Els Torreele and Martin McKee